GleamWall
中文EN

IRON Disc Medicine, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1816736 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-34.2%
TTM EPS YoY-18.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-41.3%
ROA-36.6%
ROIC (approx.)-40.5%
Asset turnover—

Leverage & solvency

Liabilities / assets13.6%
Debt / equity0.10x
Current ratio20.30x
Interest coverage-61.10x

Cash quality & payout

Operating cash flow / net income0.78x
Accruals ratio-8.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$44.08M$46.93M$45.90M$46.22M$50.33M$46.32M$27.76M$24.80M
SG&A expense$20.08M$18.14M$23.62M$20.75M$17.36M$15.09M$12.18M$9.75M
Operating income-$64.16M-$65.08M-$69.52M-$66.97M-$67.70M-$61.41M-$39.95M-$34.55M
Interest expense$1.71M$908,000$844,000$883,000$917,000$910,000$897,000$572,000
Pretax income-$59.43M-$59.46M-$63.45M-$60.44M-$62.22M-$55.20M-$33.97M-$29.28M
Income tax$109,000$69,000$51,000$88,000$102,000$52,000$119,000$176,000
Net income-$59.53M-$59.53M-$63.50M-$60.53M-$62.32M-$55.25M-$34.09M-$29.46M
EBITDA-$64.07M-$64.98M-$69.44M-$66.88M-$67.61M-$61.33M-$39.93M-$34.54M
EPS (basic)-1.53-1.54-1.65—-1.77-1.58-1.02—
EPS (diluted)-1.53-1.54-1.65—-1.77-1.58-1.02—
Weighted avg. shares (diluted)38.90M38.69M38.49M—35.18M35.02M33.32M—
Balance sheet
Cash & equivalents$89.98M$98.68M$88.91M$91.14M$140.90M$127.58M$122.91M$192.67M
Short-term investments$592.83M$619.07M$641.25M$700.01M$475.26M$522.64M$571.99M$297.45M
Current assets$697.40M$732.76M$747.46M$803.90M$627.17M$661.59M$705.60M$493.62M
PP&E, net$890,000$980,000$1.07M$1.16M$1.23M$1.29M$1.37M$751,000
Total assets$699.49M$735.07M$750.21M$806.88M$630.46M$665.06M$709.27M$496.77M
Current liabilities$34.36M$30.36M$31.14M$36.64M$26.74M$20.61M$18.74M$23.32M
Long-term debt$59.74M$59.34M$29.36M$29.16M$28.95M$28.74M$28.53M$28.32M
Total debt$59.74M$59.34M$29.36M$29.16M$28.95M$28.74M$28.53M$28.32M
Total liabilities$95.24M$90.91M$61.78M$67.05M$57.06M$50.90M$48.90M$53.19M
Shareholders' equity$604.25M$644.16M$688.43M$739.83M$573.39M$614.16M$660.36M$443.59M
Net debt-$30.24M-$39.34M-$59.55M-$61.99M-$111.96M-$98.84M-$94.39M-$164.35M
Shares outstanding38.62M38.35M38.19M37.89M35.01M34.69M34.58M29.87M
Cash flow statement
Operating cash flow-$40.20M-$44.20M-$62.24M-$43.30M-$47.80M-$47.92M-$41.38M-$27.57M
Capital expenditure$0$0$0$20,000$26,000$36,000$851,000$449,000
Free cash flow-$40.20M-$44.20M-$62.24M-$43.32M-$47.83M-$47.95M-$42.23M-$28.02M
Investing cash flow$25.33M$21.63M$58.31M-$222.89M$49.54M$51.69M-$272.63M-$1.43M
Financing cash flow$6.18M$32.34M$1.70M$216.68M$11.59M$892,000$244.25M$28.80M
Depreciation & amortization$90,000$90,000$89,000$89,000$87,000$85,000$20,000$9,000
Stock-based compensation$14.61M$13.95M$11.95M$10.04M$9.51M$8.42M$6.36M$4.33M

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.